Persistent 131I uptake in the thyroglossal duct after thyroid ablation: A case report and literature review
Open Access
- 24 April 2026
- journal article
- case report
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e48268
Abstract
Rationale: Persistent midline radioiodine uptake after thyroid remnant ablation can mimic metastatic disease and lead to unnecessary re-treatment. We report a case of persistent iodine-131 ( 131 I) uptake in the thyroglossal duct region with undetectable thyroglobulin (Tg). Patient concerns: A 45-year-old woman was found to have thyroid nodules on routine ultrasound, and further evaluation supported papillary thyroid carcinoma. Diagnoses: After total thyroidectomy and central neck dissection, post-ablation and follow-up 131 I imaging demonstrated persistent focal uptake in the midline neck. Single photon emission computed tomography, computed tomography (SPECT/CT) localized the activity to the thyroglossal duct tract, while repeated serum Tg remained undetectable and no structural lesion was identified, supporting a benign thyroglossal duct remnant. Interventions: The patient underwent total thyroidectomy with central neck dissection, followed by 100 mCi 131 I remnant ablation after thyroid hormone withdrawal. She then received levothyroxine for thyroid-stimulating hormone suppression. Six months later, levothyroxine was withdrawn again for 4 weeks, and a low-dose diagnostic 131 I scan (3 mCi) with SPECT/CT was performed. Outcomes: Diagnostic 131 I imaging at 6 months again demonstrated persistent uptake at the same thyroglossal duct site, with no uptake in the thyroid bed, undetectable Tg, and no structural evidence of recurrent disease. The patient was managed conservatively with thyroid-stimulating hormone suppression and periodic biochemical and ultrasound follow-up. Lessons: For isolated midline 131 I uptake after ablation, SPECT/CT localization along the thyroglossal duct tract combined with undetectable Tg supports a benign thyroglossal duct remnant and favors observation with structured follow-up over empiric repeat ablation.Keywords
This publication has 15 references indexed in Scilit:
- A preclinical and first-in-human study of superstable homogeneous radiolipiodol for revolutionizing interventional diagnosis and treatment of hepatocellular carcinomaActa Pharmaceutica Sinica B, 2025
- Self-assembling chemodrug fiber-hydrogel for transarterial chemoembolization and radiotherapy-enhanced antitumor immunityJournal of Controlled Release, 2025
- Rhein‐based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolizationAggregate, 2024
- Radioiodine whole body scan pitfalls in differentiated thyroid cancerEndocrine, 2024
- Cerenkov radiation shining a light for cancer theranosticsNano Today, 2024
- False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancerEndocrine, 2023
- Differentiated thyroid carcinoma: Incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapyEndocrine, 2016
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Frequent visualization of thyroglossal duct remnant on post-ablation 131I-SPECT/CT and its clinical implicationsClinical Radiology, 2015
- Undetectable Thyroglobulin in Patients With Differentiated Thyroid Carcinoma and Residual Radioiodine Uptake on a Postablation Whole-Body ScanClinical Nuclear Medicine, 2011